Posts Posts by: "Amplion"

When building a company, especially a startup, you look forward to moments that change your trajectory. So, when Mary Meeker included our analysis in her annual Internet trends presentation, it got us thinking. For those of you that don’t know, Mary Meeker is a venture capitalist from the influential Silicon Valley VC, Kleiner Perkins…(Read More)

What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how it affects the industry. While no…(Read More)

Top Blog Posts of 2016

by

As we ramp for a great 2017 we are looking back on what we did in 2016. As we ramp for a great 2017 we are looking back on what we did in 2016. In that spirit, here are the top 5 blog posts of 2016 by views. FDA Introduces a New Test Concept: “Complementary…(Read More)

This week’s Chart of the Week demonstrates recent research on the correlation between the Biomarker Coverage Percent in a company’s pipeline and the Company’s Phase 3 Likelihood of Approval. This chart depicts how as a company increases their number of trials utilizing biomarkers, they will also see an increase in their likelihood…(Read More)

This week we introduced the correlation between a company’s biomarker coverage in their clinical trial pipeline and their Likelihood of Approval. After showing correlation between approval and biomarker use, we wanted to know more about a company’s biomarker use year over year. As we dove deeper into the use of biomarkers over the…(Read More)

We held a webinar on Tuesday that allowed us to introduce our Biomarker Intelligence Maturity Model and to announce our new partnership with AdisInsight, a member of the Springer Nature family. We can assure you that the two are related.  To see for yourself check out the webinar recording…(Read More)

This week’s Chart of the Week attempts to communicate the correlation between a Company’s Precision Medicine Score and the Company’s Phase 3 Likelihood of Approval (LOA). This chart depicts how as a company increases their Precision Medicine Score, they will also see an increase in their likelihood of approval. This preliminary research…(Read More)

Three weeks ago we introduced the concept of the Biomarker Intelligence Maturity Model where we unveiled the 5 stage, 4 swim-lane model representing how companies improve biomarker intelligence management to win in drug and diagnostic development. This is the second installment of that series where we will cover the Process swim lane. Specifically, we…(Read More)

This week’s Chart of the Week attempts to communicate recent research on the percent of results you are missing in your clinical information searches (e.g. pubmed, clinicaltrials.gov, etc) without utilizing  target and synonym technologies like in BiomarkerBase. This chart depicts how many relevant and potentially game changing trials and publications manual curation…(Read More)

This week’s Chart of the Week communicates recent research on the irrelevant results found through manual review of literature versus results found through a combination of human and machine curation. This preliminary research measures the percent decrease in curation time on Clinicaltrials.gov and Pubmed.com through utilization of BiomarkerBase and its ability to…(Read More)

PageLines